UIC201806

UIC201806 is a small molecule drug candidate developed as part of a fixed-dose combination or co-administration regimen for the treatment of hyperlipidemia, specifically targeting conditions such as Hyperlipoproteinemia Type V. It has been studied in clinical trials alongside other agents (notably UI018 and UIC201602) to evaluate its safety and pharmacokinetic characteristics in healthy volunteers. The primary indication appears to be lipid modulation, aiming to reduce elevated triglycerides and non-HDL cholesterol levels in patients with severe forms of hyperlipidemia[4][7][9]. The exact mechanism of action for UIC201806 itself is not explicitly detailed in public sources, but it is likely related to lipid metabolism based on the context of its use.